In 1965, I. J. Good called the first ultraintelligent machine “the last invention that man need ever make.”
The labs say they are building it. Is it also the last investment?
I went through 200 years of tech booms and busts to find out. Free whitepaper: https://t.co/PVe9d1FFsZ
AI may change the world more than any technology in history. That says nothing about who will profit from it.
A free daily email on who gets paid: three bullets every weekday morning, 47 seconds to read.
https://t.co/wwizHPchnE
Dan Rassmussen @verdadcap joins me on Value: After Hours LIVE TODAY at 1.30pm E / 10.30am P / 5.30pm UTC / 5.30am AEDT
Watch it on the Acquirers Podcast channel: https://t.co/FFTnQqRxww………
Subscribe to be sent a reminder: https://t.co/BcE3DiwRvN
Anthropic is set to start trading on Nasdaq this week. The IMF says circular AI financing is just over $1 trillion, two-thirds of it debt. An IPO buyer is betting the builder keeps more value than its customers. https://t.co/MsA828Rsf1
the world is not internalizing charts like this
to reach 40% score on CursorBench, in July the cheapest model cost $5.14
now, it costs $0.32.
a 94% price decrease in 3 months
This is an amazing chart: Oil Demand Intensity per $1000 of real GDP
A 60% decline in oil intensity from the peak or roughly 2.5 times as much economic output per barrel.
Gains per research dollar fell about 69 percent while spending rose 6.19x, Alex Imas and Luis Garicano calculate → progress is speeding up but getting dearer, so builders must earn back more with each step.
Anthropic's IPO is reportedly about 7x oversubscribed, with up to $90.4B sought, Bloomberg's sources say → the builder layer is being priced for payback on costlier progress, and buyers carry that risk.
Nvidia lost $1.7 trillion in market value in its longest weekly losing streak since 2012, CNBC reports → the chip bottleneck owner is being repriced after Huang's exit, and AI startups face smaller checks.
Got more time? Go deeper below:
https://t.co/O2JLiK5uqf
*NEW EPISODE* VALUE: After Hours (S08 E38): The Quality Growth Playbook for Biotech | David Ferreiro
Quality Growth Investing: How to Identify Great Small-Cap Stocks
Biotech Investing Risks: Why Clinical Trials Create Opportunities
AI in Drug Discovery: Can Artificial Intelligence Transform Biotech?
When to Sell Growth Stocks: Valuation Targets and Portfolio Risk
Medical Device Stocks: Why Medtech Could Be Undervalued
Jake’s Veggies: What Mount Everest Teaches Investors About Risk Management
https://t.co/Rom4ond1CB
AI may change the world more than any technology in history. That says nothing about who will profit from it.
A free daily email on who gets paid: three bullets every weekday morning, 47 seconds to read.
https://t.co/wwizHPchnE
In 1965, I. J. Good called the first ultraintelligent machine “the last invention that man need ever make.”
The labs say they are building it. Is it also the last investment?
I went through 200 years of tech booms and busts to find out. Free whitepaper:
https://t.co/8t3m6W3rZK